ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RDHL Redhill Biopharma Ltd

0.56
-0.056 (-9.09%)
Mar 01 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 571,250
Bid Price 0.5601
Ask Price 0.5698
News -
Company Name Stock Ticker Symbol Market Type
Redhill Biopharma Ltd RDHL NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-0.056 -9.09% 0.56 19:37:51
Open Price Low Price High Price Close Price Prev Close
0.6196 0.5478 0.6196 0.5652 0.616
Trades Volume VWAP Dollar Volume Avg Volume
1,953 571,250  0.5701857  325,719 -
Last Trade Time Type Quantity Stock Price Currency
19:55:56 1  0.5697 USD

Redhill Biopharma Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 0.00 - 61.8M -71.67M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Redhill Biopharma

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RDHL Message Board. Create One! See More Posts on RDHL Message Board See More Message Board Posts

RDHL Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com